Skip to main content

Table 2 Baseline clinical characteristics of the high and low Ki-67 expression in training and validation cohort

From: Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma

  Training (n = 103) Validation (n = 48)
High Ki-67 (n = 80) Low Ki-67 (n = 23) P values High Ki-67 (n = 32) Low Ki-67 (n = 16) P values
Age (years), median (IQR) 61.0 (49.0, 67.5) 64.0 (51.3, 70.5) 0.292 54.5 (49.5, 62.0) 57.5.4 (52.5, 70.5) 0.116
Gender, no.(%)    0.721    1.000
 Male 62 (77.5) 17 (73.9)   27 (84.4) 13 (81.3)  
 Female 18 (22.5) 6 (26.1)   5 (15.6) 3 (18.7)  
ALT,(U/L), median(IQR) 34.3 (21.1, 46.5) 25.0 (19.9, 38.8) 0.207 34.4 (16.0, 35.9) 49.3 (18.3, 73.1) 0.246
AST, (U/L), median(IQR) 33.1 (24.8, 43.3) 30.0 (24.5, 42.5) 0.553 32.1 (21.9, 35.6) 44.1 (23.7, 65.4) 0.341
GGT, (U/L), median(IQR) 49.7 (30.7, 109.8) 46.1 (30.2, 66.0) 0.303 58.7 (16.0, 80.6) 36.8 (27.0, 179.5) 0.974
AFP, (µg/L), median(IQR) 44.4 (4.5, 946.8) 3.3 (1.9, 15.4) 0.000 55.7(2.5, 199.3) 3.8 (2.1, 19.5) 0.006
AFP group.no(%)    0.000    0.026
  ≤ 20 µg/L 35 (43.8) 19 (82.6)   13 (40.6) 12 (75.0)  
  20–400 µg/L 18 (22.5) 3 (13.1)   10 (31.3) 3 (18.8)  
  > 400 µg/L 27 (33.7) 1 (4.3)   9 (28.1) 1 (6.2)  
Hepatitis B, no.(%)    0.003    1.000
 Negative 16 (20.0) 9 (39.1)   7 (21.9) 4 (25.0)  
 Positive 64 (80.0) 14 (60.9)   25 (78.1) 12 (75.0)  
Hepatitis C, no.(%)    0.573    
 Negative 76 (95.0) 23 (100)   31 (96.9) 15 (93.8) 1.000
  Positive 4 (5.0) 0 (0)   1 (3.1) 1 (6.2)  
Cirrhosis, no.(%)    0.114    0.499
 Negative 21 (26.3) 10 (43.5)   7 (21.9) 5 (31.3)  
 Positive 59 (73.7) 13 (56.5)   25 (78.1) 11 (68.7)  
Tumor grade, no.(%)    0.040    0.040
 Low-grade tumor 45 (56.3) 19 (82.6)   21(65.6) 15 (93.7)  
 High-grade tumor 35 (43.7) 4 (17.4)   11 (34.4) 1(6.3)  
  1. AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase